Geron Corporation Common Stock (GERN)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits and sell at a discount to intrinsic value. Geron is not that today. It is a commercial-stage oncology company with RYTELO, but the filed numbers show losses: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $57.5M and net loss was $16.7M; in fiscal Q2 2025, the quarter ended 2025-06-30, revenue was $49.0M and net loss was $16.4M. Fiscal Q1 2026, ended 2026-03-31, showed $51.8M revenue and a $3.6M net loss. So sales are rising, but profitability is not yet proven. Annual losses remain heavy: FY2025 net loss $83.5M, FY2024 $174.6M, FY2023 $184.1M. Free cash flow was -$114.8M trailing twelve months, and the FCF yield was -14.9%. At the 2026-10-13 close of $1.20, FairStock calculates P/B of 3.53 and negative P/E. ROE is -28.28%, ROCE -4.11%, D/E 0.56. A Piotroski score of 3/9 and Altman Z of -2.53 suggest weak financial strength. The FairStock Score is 23/100, and Lynch category is none because losses occurred in each of the last four years. RYTELO may have regulatory exclusivity, but I see no durable moat in these figures. Without sustainable earnings, the market cap of $771.0M is a bet on future pipeline success, not a Graham bargain. I would want evidence of durable positive cash flow before calling it a value investment.

In plain English: Geron is a small biotech that sells a cancer-related medicine and is still losing money. Sales are growing, and losses are smaller than before, but the company has not yet turned a profit. At $1.20 a share, the price looks speculative relative to current profits because there are none; the stock depends on future drug sales.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer